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Aims Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to char-
acterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in
the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin
therapy based on elevated troponin I concentrations retrospectively.
Methods
and results
Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual
level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of
adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures
of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of
statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study.
Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardio-
vascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for
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cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and
yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to
lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the
upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute
risk reduction compared with individuals ,6 ng/L of troponin I, whereas the relative risk reduction was similar.
Conclusion In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves
prediction of cardiovascular death and cardiovascular disease.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords High-sensitivity assayed troponin I † Cardiovascular risk † Mortality † Biomarker for Cardiovascular Risk
Assessment in Europe † MONICA Risk Genetics Archiving and Monograph
Introduction
Troponin is a cardiac-specific structural protein and guidelines rec-
ommend its use for the diagnosis and management of acute coron-
ary syndrome.1 Newly established technologies allow precise
measurement of low circulating troponin concentrations in the gen-
eral population.2 These concentrations may directly reflect various
pathophysiological processes including cardiac myocyte necrosis
and apoptosis. They further correlate with the prevalence of cardio-
vascular risk factors, metabolic disorders, and cardiac hypertrophy
or dysfunction.3,4 Assessment of circulating troponin concentra-
tions using a robust, highly sensitive assay might therefore be suit-
able to predict first and subsequent adverse events.4 – 13 Broadly
comparable scoring systems for risk assessment have been devel-
oped in Europe.14,15 Whether the measurement of troponin in add-
ition to those variables contained in the scores14 – 16 is useful for
cardiovascular risk assessment remains to be elucidated.
Using the harmonized database and biobank of the Biomarker for
Cardiovascular Risk Assessment in Europe (BiomarCaRE) project
(FP7/2007–2013),17 we centrally analysed individual troponin I con-
centrations by a robust, highly sensitive assay in 74 738 individuals of
10 BiomarCaRE population-based cohorts to quantify the improve-
ment in risk prediction in a prospective setting. We further mea-
sured troponin I concentrations in 12 956 participants from the
Justification for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER)8,18 trial to globally validate
the findings and to evaluate retrospectively how the troponin I con-
centrations might better guide the eligibility for statin therapy.
Overall, we (1) evaluated the distribution of troponin I concen-
trations assayed by a highly sensitive method in population cohorts
across Europe, (2) characterized the association with cardiovascular
mortality, first non-fatal and fatal cardiovascular events, and overall
mortality, (3) determined the predictive value beyond the variables
used in the SCORE project developed by the European Society of
Cardiology (ESC), (4) tested a potentially clinically relevant cut-off
value, and (5) evaluated the improved eligibility for statin therapy
based on elevated troponin I concentrations retrospectively.
Methods
Study overview
Details of the BiomarCaRE project have been described previously.17
BiomarCaRE capitalizes on the MORGAM (MONICA Risk Genetics
Archiving and Monograph) Project,19 which harmonized data from al-
most 30 population-based studies in the MORGAM/BiomarCaRE
Data Centre in Helsinki.
The current study was designed and analysed at the BiomarCaRE
Coordinating Center in Hamburg. Troponin I had been centrally deter-
mined for all studies, including JUPITER, in the MORGAM/BiomarCaRE
laboratory. All participating studies have been approved by local ethics
review committees.
Study cohorts
Overall, the cohort consisted of 10 population-based studies involving
93 993 individuals, among them 74 738 participants with troponin I mea-
surements from five European countries. The individual cohorts were
the MONICA Brianza study, the Caerphilly Prospective study, the FIN-
RISK study, the Gutenberg Health Study (GHS), the DanMONICA
study, the Kooperative Gesundheitsforschung in der Region Augsburg
(KORA) study, the Moli-Sani Project, the Prospective Epidemiological
Study of Myocardial Infarction from Belfast (PRIME), the Scottish Heart
Health Extended Cohort Study, and the Study of Health in Pomerania
(SHIP). Each cohort is based on a well-defined population (Supple-
mentary material online, Table S1). Full details of when the baseline
data were collected are provided in Supplementary material online,
Figure S1. Cohort descriptions are provided in Supplementary material
online, Box S1. The final dataset to test the hypothesis that troponin I
adds to risk prediction, comprised 74 738 participants. The harmonized
variables included baseline information on smoking status, body mass
index (BMI), systolic blood pressure, history of diabetes, total- and
high-density lipoprotein cholesterol, history of myocardial infarction
(MI), and history of stroke, and anti-hypertensive medication, as well
as high-sensitivity C-reactive protein (CRP), N-terminal pro-B-type
natriuretic peptide (NT-proBNP), and estimated glomerular filtration
rate (eGFR, CKD-EPI formula).20 Subjects with a systolic blood pressure
.140 mmHg and/or anti-hypertensive medication were classified as
hypertensive.
Study outcome
The outcome measures in our analysis were (1) cardiovascular mortal-
ity, (2) the first occurrence of a major cardiovascular event, and (3)
overall mortality. The definition of cardiovascular mortality was similar
to that of the ESC described by Conroy et al.14 but based in the data
harmonized in the MORGAM Project.15 First major cardiovascular
events include the first fatal or non-fatal definite or possible MI or cor-
onary death, unstable angina, cardiac revascularization, ischaemic stroke,
and unclassifiable death. Overall mortality was defined as mortality due
to any cause during the follow-up time. More details of the event
classification are provided in Supplementary material online and the
MORGAM Manual.15
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The risk of cardiovascular mortality, cardiovascular disease, and total
mortality was calculated using variables of the Systematic COronary
Risk Evaluation—SCORE developed by the ESC. Applicability of this
score is described by Perk et al.15 and Conroy et al.14
To predict non-fatal or fatal cardiovascular events, we included only
those participants in the analyses who did not have a prior history of ma-
jor cardiovascular disease such as MI, hospitalized unstable angina, cor-
onary artery bypass grafting, percutaneous transluminal coronary
angioplasty, or ischaemic or haemorrhagic stroke.
To enable potential translation into the clinical situation, we recom-
mend establishing a troponin I cut-off. We selected a cut-off value of
6 ng/L as it approximates the upper quintile of 5.9 ng/L of the overall dis-
tribution in the aggregated BiomarCaRE population. To examine how
the cut-off .6 ng/L improves risk prediction, we computed HRs,
C-statistics, and net reclassification improvement for all endpoints.
To validate our findings and test a more individualized eligibility for
statin therapy, we estimated the effects of statin therapy among indivi-
duals with high (.6 ng/L) and lower (≤6 ng/L) troponin I concentra-
tions using the database of the globally conducted JUPITER trial. The
selection of 6 ng/L was justified as it approximates the upper quintile
in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L). The design and results
of the JUPITER trial are described in Supplementary material online,
Box S1, and in detail elsewhere.8,18
Laboratory procedures
Serum troponin I was determined in the BiomarCaRE core laboratory
using a highly sensitive troponin I immunoassay (Abbott Diagnostics,
USA, ARCHITECT i2000SR). The limit of detection for the assay was
1.9 ng/L (range 0–50 000 ng/L). The assay had a 10% coefficient of
variation at a concentration of 5.2 ng/L. The high-sensitivity assayed
troponin I is denoted as ‘troponin I’ during the course of the manuscript.
The study-specific intra- and inter-assay coefficients of variation are
described in Supplementary material online, Table S2. N-terminal
pro-B-type natriuretic peptide levels were measured on the ELECSYS
2010 and the Cobas e411 using an electrochemiluminescence immuno-
assay (ECLIA, Roche Diagnostics). The analytical range is 5–35.000 ng/L.
C-reactive proteins were measured with the routine laboratory using an
Abbott Architect c8000 system and the CRP Vario immunoassay.
Statistical methods
Initial descriptive associations between baseline variables and troponin I
were assessed using linear mixed models or ordinary linear models with
the cubic root of troponin I as the dependent variable depending on
whether the association was being examined in the overall BiomarCaRE
cohort or in a single cohort. To measure a standardized association be-
tween troponin I and other baseline variables, we used a partial correl-
ation coefficient.21 To visualize these associations, an effect plot of a
model including linear, quadratic terms, and sex interactions was pro-
duced using the methods of Fox.22
Survival curves for cardiovascular disease events, cardiovascular mor-
tality, and overall mortality were computed according to fifths of the
troponin distribution. Quintiles were computed in the overall Biomar-
CaRE cohort using linear quantile mixed models23,24 with troponin I as
the dependent variable. These models contained no predictors, just an
intercept, fixed, and random. The latter was allowed to vary between
cohorts. The upper quintile was 5.9 ng/L.
Sex- and cohort-stratified Cox proportional hazards models for car-
diovascular disease events, cardiovascular mortality, and overall mortal-
ity were computed using the individual-level data from the available
cohorts. For these analyses, troponin I was used after applying the cubic
root transformation, categorized using quintiles as defined in the overall
BiomarCaRE cohort, and using the cut-off of 6 ng/L which approximates
the upper quintile of 5.9 ng/L. The Cox models for all three considered
endpoints were adjusted for the SCORE14,15 variables (systolic blood
pressure, total cholesterol, smoking status, sex as strata, and age as
time scale). Additional models exchanging troponin I with CRP,
NT-proBNP, and eGFR were also computed. C-reactive protein and
NT-proBNP were log-transformed for these analyses.
The C-index25,26 and the net reclassification improvement (NRI)27–29
were used to quantify the added predictive value of troponin I beyond
that from a model including the variables in SCORE. This was repeated
exchanging troponin I with CRP, NT-proBNP, and eGFR. For these ana-
lyses, the 10-year event probabilities were computed using a Weibull
curve fitted over age and adjusted by the linear predictor of the esti-
mated Cox model. For the computation of C-indices and NRI, the
follow-up times were censored at 10 years. Ten-fold cross validation
was used to control for the over-optimism of calculating performance
measures on the same dataset from which the models were computed.
The risk categories used for the NRI analysis were,1%, 1 to ,5%, 5 to
,10%, and ≥10%15 for cardiovascular mortality, cardiovascular disease,
and overall mortality. A version of NRI appropriate for survival analyses
was computed using the Kaplan–Meier method.28 The overall NRI does
not represent a proportion and is therefore reported as a decimal num-
ber between 22 and 2 rather than a percentage, as recommended by
Leening et al.29 Differences in C-statistics (with 95% CIs) after the add-
ition of troponin I to the model consisting of cardiovascular risk factors
were computed using the method described by Antolini et al.30 Cox re-
gressions, C-indices, and NRIs described above were also computed for
the age groups ,45, 45–54, 55–64, and ≥65 years at baseline.
To assess the calibration of the models, we used an extension of the
Hosmer–Lemeshow test for survival analyses proposed by Demler
et al.31 Tenths of the risk distribution were used.
A two-sided P-value of ,0.05 was considered statistically significant.
All statistical methods were implemented in R statistical software ver-
sion 3.2.132 (www.R-project.org). For more detailed statistical descrip-
tion, please see Supplementary material online, Statistical methods.
Results
Demographic characteristics of the study
population
The characteristics of the BiomarCaRE study participants are pro-
vided in Table 1. Overall, the study comprised 49 104 (52.2%)
men and 44 889 (47.8%) women. Mean age at baseline was 52.2
(interquartile range 17.8) years, the age-range was 20–99 years.
The median follow-up time was 13.8 years for cardiovascular mor-
tality and cardiovascular disease events and 12.1 years for overall
mortality (maximum of 28 years of follow-up). Of the participants,
4516 (5.7%) died of cardiovascular causes, 7722 (10.3%) had their
first cardiovascular event, and 12 688 (13.5%) died from any cause.
The prevalence of daily smokers at baseline was 26.7%. 42.1% had
hypertension and 5% diabetes.
Distribution of troponin I and its
association with cardiovascular risk
factors and subclinical phenotypes
Troponin I was determined in 74 738 participants. Comparative in-
formation among individuals with and without troponin I measure-
ments is provided in Supplementary material online, Table S3. The
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median value of troponin I was 2.7 ng/L, the upper quintile limit
was calculated at 5.9 ng/L. The distribution of troponin I concentra-
tions among the overall population is displayed in Supplementary
material online, Figure S2. Detailed distributions of troponin I for
each cohort are outlined in Supplementary material online, Figure
S3 and Table S1.
In age-adjusted models the cube root of troponin I was higher in
males than in females (regression coefficient 0.213, P, 0.001) and
in individuals with diabetes than in those without diabetes (coeffi-
cient 0.106, P, 0.001). It increased in a non-linear fashion with sys-
tolic blood pressure in the overall BiomarCaRE cohort, and—as
assessed in GHS only—with left ventricular mass and the extent
of carotid atherosclerosis (each P, 0.001). Furthermore, troponin
I decreased with eGFR, assessed in the overall BiomarCaRE cohort
(Supplementary material online, Figure S4). Overall, associations of
troponin I with cardiovascular risk factors and phenotypes are
only moderate, with the highest partial correlations observed for
left ventricular mass (females r ¼ 0.13, males r ¼ 0.24), carotid pla-
que (females r ¼ 0.10, males r ¼ 0.11), and eGFR (females r ¼ 0.08,
males r ¼ 0.14) (Supplementary material online, Figure S4 and in
‘Measuring and definition of phenotypes in Gutenberg Health
Study’).
Troponin I concentrations and association
with cardiovascular outcomes and
all-cause mortality
Figures 1 and 2 display unadjusted survival curves and fully adjusted
hazard ratios across fifths of the troponin I distribution indicating
strong associations with cardiovascular mortality, first cardiovascu-
lar event, and overall mortality. An approximately doubling of risk
was observed across increasing fifths. Individuals in the top fifths
of the troponin I distribution compared with the bottom fifth had
a 160% increase in mortality from cardiovascular causes (HR 2.60,
95% CI 2.29–2.94; P, 0.001), 92% increase in risk for a first cardio-
vascular event (HR 1.92, 95% CI 1.76–2.10; P, 0.001), and a 63%
increase in the risk of overall mortality (HR 1.63, 95% CI 1.53–1.75;
P, 0.001). Hazard ratios for cardiovascular mortality, cardiovascu-
lar disease, and overall mortality were broadly similar in all sub-
groups (Supplementary material online, Figure S5). The association
between troponin I (treated as continuous variable) and the three
outcome measures according to each cohort is displayed in Supple-
mentary material online, Figure S6.
Troponin I and prediction of
cardiovascular mortality, cardiovascular
disease, and overall mortality
The addition of troponin I to variables of the ESC SCORE for pre-
diction of cardiovascular mortality (C-index of 0.84 with 95% CI
0.82–0.86) led to an increment in the C-index of 0.007 with 95%
CI 0.005–0.009. The addition of troponin I in the overall cohort
to a prognostic model for first cardiovascular events and total mor-
tality (C-index of 0.80 with 95% CI 0.79–0.81 for both events) in-
creased the C-index by 0.004 with 95% CI 0.003–0.005 for
cardiovascular disease and the C-index by 0.003 with 95% CI
0.002–0.004 for total mortality (Table 2). After stratification ac-
cording to decades of age, the addition of troponin I led to a greater
incremental risk prediction with rising age for all three investigated
endpoints: 0.010 with 95% CI 0.006–0.014 for cardiovascular mor-
tality and even 0.010 with 95% CI 0.008–0.013 for total mortality,
and 0.018 with 95% CI 0.012, 0.024 for first cardiovascular events
(Table 2). Most interestingly, baseline C-indices decreased with in-
creasing age suggesting that the inclusion of additional variables
such as troponin I become more valuable over the life time.
The magnitude of an incremental effect achieved by the inclusion
of troponin I into the models is comparable with that obtained from
the separate addition of established cardiovascular risk factors, al-
though this varies between prediction of cardiovascular death and
CVD risk prediction (Supplementary material online, Table S4).
The C-statistics for each biomarker including troponin I, CRP,
NT-proBNP, and eGFR (CKD-EPI formula) when added to the
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Table 1 Baseline characteristics of the study
population
Characteristics
Number of cohorts, n 10
Number of individuals, n 93 993
Years of baseline examinations (years) 198222012
Men, n (%) 49 104 (52.2)
Women, n (%) 44 889 (47.8)
Age at baseline examination (years) 52.2 (42.9, 60.7)
Cardiovascular risk factors
Daily smoker, n (%) 24 828 (26.7)
Diabetes, n (%) 4655 (5.0)
Hypertensiona, n (%) 39 227 (42.1)
Body-mass-index (kg/m2) 26.3 (23.6, 29.4)
Systolic blood pressure (mmHg) 132.0 (120.0, 147.0)
Total cholesterol (mmol/L) 5.7 (5.0, 6.5)
HDL cholesterol (mmol/L) 1.4 (1.2, 1.7)
Medication
Anti-hypertensive, n (%) 17 682 (19.0)
Troponin
Information on troponin I, n (%) 74 738 (79.5)
Troponin I (ng/L) 2.7 (1.5, 4.6)
Other biomarkers
CRP (mg/L) 1.5 (0.7, 3.1)
NT-proBNP (pg/mL) 49.7 (25.8, 93.9)
eGFR (Crea) (mL/min/1.73 m2) 93.7 (82.4, 103.5)
Endpoints
Cardiovascular mortality, n (%) 4516 (5.7)
Cardiovascular disease, n (%) 7722 (10.3)
Total mortality, n (%) 12 688 (13.5)
Baseline characteristics are presented as absolute and relative frequencies for
categorical variables, and quartiles for continuous variables as well as ranges in
years for years of baseline examinations.
Troponin I measured by a high-sensitivity assay.
aHypertension was defined as anti-hypertensive medication and/or systolic
RR. 140 mmHg.
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Figure 1 Survival curves according to fifths of the troponin I distribution in the study population. The P-value given in the survival curves is for
the log-rank test. The troponin I quintiles, computed in the overall population via linear quantile mixed models, are 2.5, 2.8, 5.4, and 5.9 ng/L. The
number of cohorts contributing to the figure decreases gradually over the 28 years, and includes only the Glostrup cohort at the end of follow-up.
The number of persons at risk at 27 years of the follow-up according to troponin I fifths in increasing order is 1288, 162, 669, 30, 155 for car-
diovascular mortality and total mortality, and 1201, 145, 601, 26, 136 for cardiovascular disease.
Figure 2 Hazard ratios according to fifths of the troponin I distribution in the study population. The troponin I quintiles, computed in the overall
population via linear quantile mixed models, are 2.5, 2.8, 5.4, and 5.9 ng/L. The hazard ratios come from Cox models adjusted for variables of the
ESC SCORE (cardiovascular mortality, total mortality) and ACC/AHA score (cardiovascular disease). Age was used as the time scale. The models
were stratified by sex and cohort. ns stands for non-significant (P ≥ 0.05), *0.01 ≤ P, 0.05, **0.001 ≤ P, 0.01, ***0.0001 ≤ P, 0.001, and
****P, 0.0001.
S. Blankenberg et al.2432
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ESC SCORE are shown in Supplementary material online, Table S4.
We observed similar performance of each biomarker.
Examining C-statistics for prediction at 1, 5, and 10 years of the
follow-up, the decrease in C-indices regarding cardiovascular dis-
ease endpoint could be noticed for each biomarker (Supplementary
material online, Figure S7).
Calibration of the Cox models including troponin I is shown in
the Supplementary material online, Figure S8. No major miscalibra-
tion could be observed in the plots and the Hosmer–Lemeshow
test for cardiovascular mortality showed no significant deviation be-
tween predicted and observed cardiovascular mortality (P ¼ 0.094,
x2 ¼ 13.6), whereas the test was formally significant for cardio-
vascular disease (P, 0.001, x2 ¼ 31.2 and overall mortality
(P, 0.001, x2 ¼ 34.3).
Reclassification analyses for the addition of troponin I to a model
consisting of ESC SCORE variables are presented in Figure 3 and
Table 3. The addition of troponin I to the ESC score for cardiovas-
cular mortality led to an NRI of 0.048 (95% CI 0.030–0.066), 0.038
(95% CI 0.020–0.056) for cases and 0.010 (95% CI 0.008–0.012) for
non-cases. In particular, in individuals above the age of 65 years, the
NRI was 0.039 (95% CI from 0.020–0.059). The addition of tropo-
nin I to the ESC SCORE algorithm produced an NRI of 0.017 (95%
CI from 0.008–0.025), 0.010 (95% CI 0.002–0.018) for cases and
0.006 (95% CI 0.005–0.008) for non-cases for cardiovascular dis-
ease and an NRI of 0.013 (95% CI from 0.007–0.020), 0.005 (95%
CI 20.001 to 0.011) for cases, and 0.008 (95% CI 0.007–0.010)
for non-cases for total mortality. Reclassification tables showing es-
timates of the expected number of reclassifications per risk category
for cases and non-cases are provided in Table 3.
Association and prediction above the
upper quintile
The strong improvement of risk prediction for troponin I concentra-
tion above 6 ng/L could be demonstrated for cardiovascular mortality,
yielding an HR of 1.87 (95% CI 1.72–2.03; P, 0.001), C-index differ-
ence of 0.010 (95% CI 0.007–0.012; P, 0.001), and NRI of 0.0743
(95% CI 0.0487–0.0999), 0.061 (95% CI from 0.036–0.086), for cases
and 0.013 (95% CI 0.011–0.016) for non-cases. Detailed results for
cardiovascular disease and overall mortality endpoints are also dis-
played in Supplementary material online, Table S5.
Troponin I, statin therapy, and outcome
To identify subjects with potentially improved eligibility for statin
therapy based on elevated troponin I, we assessed the risk reduction
by rosuvastatin in the JUPITER trial according to troponin I levels be-
low and above 6 ng/L, a level, which is near the upper troponin I
quintile of 5.8 ng/L achieved in this trial.
Similar to the BiomarCaRE population, individuals with troponin I
concentrations above that level had an increased risk of cardiovas-
cular disease (HR ¼ 1.93, 95% CI 1.31–2.84; P, 0.0008) and over-
all mortality (HR ¼ 2.25, 95% CI 1.60–3.15; P, 0.001). A formal
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Table 2 Changes in C-statistics for 10-year risk prediction of cardiovascular mortality and cardiovascular disease and
total mortality endpoints after adding of continuous troponin I to established risk scores in the overall cohort and
according to age groups
ESC SCORE C-index (95% CI) ESC SCORE C-index difference (95% CI) P-value
Cardiovascular mortality
All 0.84 (0.82, 0.86) 0.007 (0.005, 0.009) ,0.001
,45 0.83 (0.75, 0.91) 0.002 (20.003, 0.007) 0.50
45–54 0.75 (0.71, 0.79) 0.014 (0.006, 0.021) ,0.001
55–64 0.75 (0.72, 0.77) 0.010 (0.005, 0.015) ,0.001
≥65 0.72 (0.69, 0.75) 0.010 (0.006, 0.014) ,0.001
Cardiovascular disease
All 0.80 (0.79, 0.81) 0.004 (0.003, 0.005) ,0.001
,45 0.83 (0.79, 0.87) 0.001 (20.002, 0.004) 0.66
45–54 0.74 (0.72, 0.77) 0.006 (0.002, 0.009) ,0.001
55–64 0.69 (0.67, 0.71) 0.007 (0.004, 0.009) ,0.001
≥65 0.64 (0.62, 0.67) 0.018 (0.012, 0.024) ,0.001
Total mortality
All 0.80 (0.79, 0.81) 0.003 (0.002, 0.004) ,0.001
,45 0.73 (0.69, 0.76) 0.000 (20.001, 0.000) 0.32
45–54 0.70 (0.67, 0.72) 0.004 (0.001, 0.007) ,0.0024
55–64 0.68 (0.66, 0.70) 0.008 (0.005, 0.011) ,0.001
≥65 0.67 (0.66, 0.69) 0.010 (0.008, 0.013) ,0.001
The ESC SCORE variables were used to adjust the models. C-index difference means the difference to the ‘base model’ where troponin I was not used. Age is used as the time scale
of the Cox models (so they are implicitly adjusted for age). A Weibull baseline hazard was used to compute the event probabilities (from the Cox models). These (10 years) event
probabilities are used to compute the C-indices.
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test for interaction showed that the relative risk reduction for car-
diovascular events and overall mortality in those receiving rosuvas-
tatin was similar in both groups, whereas the absolute risk reduction
for cardiovascular events and mortality was higher in those indivi-
duals with troponin I concentration .6 ng/L (Table 4).
Discussion
Based upon harmonized individual level data and a centrally standar-
dized troponin I measurement in 74 738 individuals from population-
based studies, our analyses suggest that the addition of troponin I to
conventional risk factors improves risk prediction in particular for
cardiovascular death as well as any first cardiovascular event and
overall mortality in the general population. The upper quintile of
troponin I in the study population corresponding to 6 ng/L might
provide a clinically applicable concentration to identify individuals at
high risk for cardiovascular death.
Clinical implications of troponin I
measurements in apparently healthy
subjects at risk for cardiovascular disease
The current study has several important implications. First, our re-
sults indicate that troponin I concentrations in apparently healthy
subjects are continuously associated with fatal cardiovascular events
and to a lesser extent with incident cardiovascular disease as well as
overall mortality.
Comparing the improvement by troponin I in risk prediction with
other biomarkers such as CRP, NT-proBNP, and eGFR, we
observed the following trends: CRP concentration showed continu-
ous associations of similar magnitude with risk of coronary heart dis-
ease, ischaemic stroke, vascular mortality, and death from several
cancers and lung disease. Associations with ischaemic vascular
disease depend considerably on conventional risk factors and other
markers of inflammation.33 Everett et al.34 demonstrated within the
Women’s Health Initiative the relationship between NT-proBNP
and incident cardiovascular events. Several features suggest that
these findings are significant: there was a linear relationship between
risk and NT-proBNP values; the hazard ratios were consistent
across several methods of adjustment; NT-proBNP levels predicted
each individual component of the composite endpoint; and there
were no interactions with any other cardiac risk factor or patient
descriptor.34,35 Ledwidge et al.36 and Huelsmann et al.37 also de-
monstrated the efficacy of primary prevention strategies in patients
with elevated NT-proBNP levels highlighting its potential utility for
risk prediction. Recent studies suggest that targeting intensified
cardiovascular care on the basis of NT-proBNP levels may reduce
events, but this was seen in populations at higher risk than in those
from observational studies. An exponential increase in risk for all-
cause and cardiovascular mortality was observed at low eGFR.38
The pattern of an increased risk for all-cause and cardiovascular
mortality for lower eGFR in high-risk cohorts38 is comparable
with that observed in general population cohorts.39 Thus, we can-
not show which biomarker performs better for risk prediction of
cardiovascular events. But we could prove with our additional ana-
lyses, as displayed in Supplementary material online, Figure S7, that
troponin I presents itself a roughly comparable predictor for cardio-
vascular events.
Second, the level of troponin I is moderately related to the extent
of other cardiovascular risk phenotypes for vascular atherosclerosis
and cardiac function. Third, as a specific marker of myocardial ne-
crosis, troponin I adds information on risk prediction beyond vari-
ables of the European SCORE. According to age-stratified
analyses, the troponin I-based risk prediction information is particu-
larly useful among individuals aged .65 years. Below the age of 45,
assessment of troponin I is apparently not useful in improving risk
prediction. Fourth, 6 ng/L of troponin I correspond to the upper
quintile of the general population and might offer a reasonable cut-
off value for direct clinical application. This population potentially
benefits most from preventive therapy strategies such as statin ther-
apy in terms of absolute risk reduction. Whether or not the same
intervention threshold might maximize benefit from aspirin or other
preventive therapies needs to be tested in appropriate trial popula-
tions.40 Finally, we used a commercially available assay which easily
and reliably detects very low levels of troponin I and thus opens the
possibility of stratifying risk by use of a cardiac-specific biomarker.
Importantly, the technical imprecision value of 5.2 ng/L—the so-
called 10% coefficient of variation—is below the proposed cut-off
value of 6 ng/L, which allows a precise detection of troponin I for
clinical decision-making.
Troponin I, cardiovascular phenotypes,
and prognosis
Troponin I is mainly released by cardiac myocytes and cor-
relates with subclinical risk phenotypes such as the degree of
Figure 3 Net reclassification improvement of 10-year risk pre-
diction by troponin I over model with variables used in the ESC
SCORE (cardiovascular mortality, total mortality, and cardiovascu-
lar disease) in the overall cohort and according to age groups. The
risk categories used are ,1%, 1 to ,5%, 5 to ,10%, and ≥10%.
Net reclassification improvement is presented as a number with a
theoretical range between 22 and 2.
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atherosclerosis, ventricular hypertrophy, and vascular stiffness.
Consequently, the detection of very low circulating levels provides
additional information on risk beyond that obtained from modifiable
cardiovascular risk factors, which already explain a substantial pro-
portion of cardiovascular risk.15,41 The addition of this biomarker to
models including traditional risk factors adds similar predictive infor-
mation in all cardiovascular risk subgroups. When addressing fatal
cardiovascular outcome, the magnitude of additional risk prediction
achieved by inclusion of troponin I into the risk models is similar to
that obtained from any single accepted risk factor. Elevated troponin
I at baseline is most probably due to subclinical cardiac pathology
which increases the risk of cardiovascular death or major CVD
events years later. Therefore, the predictive value of troponin I is
stronger in populations at higher cardiovascular risk, and becomes
more evident with increasing age. The clinical significance of this is
that elevated troponin I should trigger careful examinations to
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Table 3 Net reclassification improvement by endpoint with estimates of the expected number of reclassifications per
risk category for cases and non-cases
ESC SCORE and troponin I Reclassified
up, n (%)
Reclassified
down, n (%)
NRI (95% CI)
<1% 1 to <5% 5 to <10% ≥10%
Pattern A (for cardiovascular mortality)
Cases
,1% 107 12 0 0 91 (6.4) 37 (2.6) 0.038 (0.020, 0.056)
1 to ,5% 8 433 36 2
5 to ,10% 0 15 283 41
≥10% 0 0 14 408
Non-cases
,1% 37 029 392 3 3 993 (1.6) 1625 (2.6) 0.010 (0.008, 0.012)
1 to ,5% 856 17 354 368 41
5 to ,10% 0 521 4047 186
≥10% 0 0 248 2159
Overall 0.048 (0.030, 0.066)
Pattern B (for cardiovascular disease)
Cases
,1% 44 2 0 0 96 (3.0) 65 (1.9) 0.010 (0.002, 0.018)
1 to ,5% 4 482 30 2
5 to ,10% 0 30 823 62
≥10% 0 0 31 1668
Non-cases
,1% 15 099 277 1 0 1013 (1.8%) 1377 (2.4%) 0.006 (0.005, 0.008)
1 to ,5% 373 21 383 373 12
5 to ,10% 0 543 10 078 350
≥10% 0 0 461 8316
Overall 0.017 (0.008, 0.025)
Pattern C (for total mortality)
Cases
,1% 140 5 0 0 96 (2.1) 77 (1.6) 0.005 (20.001, 0.011)
1 to ,5% 5 613 26 1
5 to ,10% 0 20 778 64
≥10% 0 0 52 2896
Non-cases
,1% 18 299 303 3 0 1035 (1.6) 1565 (2.5) 0.008 (0.007, 0.010)
1 to ,5% 399 21 741 355 14
5 to ,10% 0 661 10 067 360
≥10% 0 0 505 11 232
Overall 0.013 (0.007, 0.020)
Net reclassification improvement is presented as a number with a theoretical range between 22 and 2.
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precisely diagnose the underlying cardiac problem, and to treat it ap-
propriately, which may prevent or postpone the future adverse
events.
Importantly, the addition of troponin I improves overall risk esti-
mation particularly among individuals above the age of 65, in whom
the traditional risk prediction scores are apparently less informative.
Overall, the predictive strength of troponin I becomes more evident
with increasing age.
Strengths and limitations of the study
Our study has several strengths and limitations. Since 1998, we have
harmonized data from population-based cohort studies in the MOR-
GAM Data Centre in Helsinki providing the best possible endpoint
validation consistent with and supported by the European Union
framework programmes. Furthermore, we performed all troponin I
measurements of the cohorts and JUPITER participants in one central
laboratory within the frame of the EU-FP7 programme BiomarCaRE.
Standardized epidemiological and laboratory procedures based on in-
dividual level data allow for the best possible risk stratification ana-
lyses. Additionally, we compared prediction analyses in different
European regions and demonstrated generalizability across all partici-
pating regions. The association with outcomes showed consistently
increasing risk with increasing troponin I concentrations—far below
the so-called 99th percentile. Using a validation strategy, individuals
above a specific cut-off level near the upper quintile benefit with
greater absolute risk reduction from preventive therapies such as sta-
tin therapy. This value is still above the technical imprecision value
of 5.2 ng/L. These results are also in line with those observed in the
LIPID trial. Here, patients receiving pravastatin demonstrated a slight-
ly greater reduction in troponin I with treatment and the delta of
troponin I (from baseline pre-treatment concentrations) was an
independent predictor of cardiovascular risk and mortality among pa-
tients receiving pravastatin.42
Several limitations merit consideration. In total, .93 000 indivi-
duals were investigated in 10 cohorts. We encountered missing in-
formation concerning important variables in some cohorts. For
example, the GHS study and the SHIP study did not include informa-
tion on cardiovascular disease as an endpoint, the Caerphilly study
did not include information on low- and high-density cholesterol.
Additional limitation is hidden in what could be interpreted as
inconsistent results, when regarding the association between tropo-
nin I and the three outcomes according to each cohort as displayed
in Supplementary material online, Figure S6. The results presented
by the Brianza and the FINRISK studies are less strong than in
most other cohorts. Age, sex, and careful exclusion of people
with prevalent cardiac disease might have contributed to such differ-
ences. FINRISK, Brianza, and KORA are three cohorts with a high
percentage of young people. The proportion of women is about
the same in FINRISK compared with the other cohorts. Finnish
women tend to have relatively little CHD43,44 in international
comparisons, clearly differing from Finnish men. Furthermore, in
FINRISK the exclusion of people with prevalent CVD was based
on hospital discharge register diagnoses, whereas in most other
cohorts exclusions were based on self-reported history of CVD.
On the contrary, according to Figure S5, risk factors for CVD (like
diabetes and hypertension) do not seem to influence endpoints.
Since troponin I is very specific for heart problems and even minor
elevations most likely reflect subclinical heart disease, all of these
points may play a role in explaining the weaker associations. More-
over, a measurement error could be possible. Earlier studies
showed that evaporation could be a problem giving rise to higher
concentrations in older samples.
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Table 4 Association of troponin I with selected endpoints in the JUPITER trial
Endpoint N events/N at risk
for individuals with
troponin I >6
Adjusteda HR in the
placebo group
Pattern A (association of troponin I. 6 with selected endpoints)
Cardiovascular disease 45/1204 1.93
Total mortality 64/1204 2.25
Troponin I category Rosuvastatin Placebo Absolute risk
reduction
HRa (95% CI) P-value†
N events Incidence rate N events Incidence
rate
Pattern B (cardiovascular disease as an endpoint)
≤6 ng/L 36 0.31 73 0.65 0.34 0.47 (0.32–0.71) ,0.0003
.6 ng/L 22 0.87 45 1.61 0.74 0.54 (0.32–0.90) 0.018
Pattern C (total mortality as an endpoint)
≤6 ng/L 79 0.64 88 0.74 0.10 0.89 (0.66–1.21) 0.46
.6 ng/L 41 1.49 64 2.11 0.62 0.70 (0.47–1.03) 0.07
aAdjusted for age, sex, race, hypertension, cigarette smoking, BMI, total and HDL cholesterol, family history of coronary heart disease, and Ln(hsCRP).
†P-value for interaction between troponin I category and active rosuvastatin for cardiovascular disease ¼ 0.80 and for overall mortality ¼ 0.78. The model testing for interaction
adjusts for the covariates noted above and including terms for the main effects of drug and troponin I category. The incidence rates are per 100 person-years of observation. The
median follow-up time in this sample was 2 years.
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A further limitation is that we cannot be sure that our proposed
cut-off value of 6 ng/L, when applied in an everyday clinical setting,
would improve the outcome of preventive strategies. While data
driven approaches such as ours for threshold estimation are known
to be over-optimistic, the bias is minimal with large sample size.45 In
addition, troponin concentrations vary according to population. Net
reclassification improvement results depend on the number and the
level of the thresholds used to define the risk categories, and for this
reason we adopted the widely recommended clinically meaningful
categories appropriate for the prediction of cardiovascular dis-
ease.28 Finally, some degree of miscalibration was detected when
addressing overall mortality and CVD outcome. However, given
the large sample size and the consistency of predictions for cardio-
vascular mortality, this effect appears rather small.
Conclusion
In conclusion, the addition of troponin I to established risk
models consistently improved risk prediction in apparently
healthy individuals drawn from the general population. As estab-
lished risk models provide less information with increasing age,
the addition of troponin I might be particularly helpful in those
.65 years. Troponin I determination might support the selection
of those individuals, who would benefit most from preventive
strategies.
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